Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J Pharma Revenues up 3% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Financial News

J&J Pharma Revenues up 3% in the Quarter

Growth of DARZALEX, TREMFYA, STELARA, ERLEADA, INVEGA SUSTENNA, and TRINZA, partially offset by declines for REMICADE and IMBRUVICA.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
3Q Revenue: $23.8 billion (+2%)
3Q Earnings: $4.5 billion (+22%)
YTD Revenue: $71.2 billion (+3%)
YTD Earnings: $14.4 billion (-11%)
Comments: Pharmaceutical sales were up 3% to $13.3 billion, driven by DARZALEX (daratumumab), a biologic for the treatment of multiple myeloma, TREMFYA (guselkumab), a biologic for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-gen androgen receptor inhibitor for the treatment of prostate cancer, and INVEGA SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia. The Janssen COVID-19 Vaccine (Ad26.COV2.S) sales were $489 million in the quarter, down 3%. Growth in the quarter was partially offset by declines in sales of REMICADE (infliximab), a biologic for the treatment of several immune-mediated inflammatory diseases and IMBRUVICA (ibrutinib), an oral, once daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters